Clinical Trial Update: Neoadjuvant Therapy With Ensartinib Combined With Chemotherapy for ALK-positive Non - Small Cell Lung Cancer (NSCLC) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 neoadjuvant trial testing ensartinib in combination with chemotherapy for ALK-positive non-small cell lung cancer, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Ensartinib (Ensartinib)

Snippet

Sponsor: Tang-Du Hospital | Conditions: NSCLC (Non-small Cell Lung Cancer) | Phase 1, Phase 2 | Status: RECRUITING